MANKIND

Growth Story Continues

Mankind Pharma has witnessed a strong breakout backed by surging volumes, indicating fresh buying interest. The weekly RSI at 66.45 reflects strengthening bullish momentum without entering the overbought zone. The stock remains well-positioned for a continuation of the uptrend. Fundamental View Mankind Pharma trades at 53.7x TTM P/E (EPS: ₹46.3). Based on its 3-year PAT growth trend and management's outlook for sustained double-digit earnings growth, the forward EPS is estimated at ₹54–56, implying a forward P/E of ~47–48x. The recent quarter delivered healthy revenue and profit growth with improving margins, while management remains optimistic on double-digit revenue growth and margin expansion in FY27.